SAN FRANCISCO, Sept. 16, 2024 /PRNewswire/ -- Darmiyan, Inc., a pioneer in brain technology, is proud to announce the launch of the BrainSee Platform, integrating the first-of-its-kind FDA-approved ...
The Food and Drug Administration has granted de novo authorization to artificial intelligence (AI) diagnostic tools from Imvaria and Darmiyan. Imvaria received authorization for a tool that analyzes ...
SAN FRANCISCO, May 29, 2025 /PRNewswire/ -- Darmiyan, Inc., a leading brain health technology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's ...
The US government has reportedly approved AI-based memory loss prediction software for the first time. Darmiyan, a San Francisco-based brain imaging analytics company, says the FDA has granted De Novo ...
Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More The brain is a complex beast. It has 100 billion nerve cells — called ...
Darmiyan is pleased to announce that the company's first product BrainSee has obtained from the FDA a breakthrough designation granted for innovative medical devices. Through the breakthrough program ...
The FDA has granted a de novo clearance to an artificial intelligence program capable of reading a standard brain MRI scan and predicting a patient’s chances of progressing from mild cognitive ...
Darmiyan, Inc., a leading company in brain health innovation, announces the US FDA's approval of its first-in-class (De Novo) clinical test, BrainSee. This approval marks a pivotal advancement in ...
An estimated 14 million older adults in the United States live with mild cognitive impairment (MCI). While many will never progress to dementia — experiencing stable or even improved cognitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback